FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966938034> ?p ?o ?g. }

• W2966938034 endingPage "452" @default.
• W2966938034 startingPage "452" @default.
• W2966938034 abstract "Abstract Background: Non-endemic Burkitt lymphoma (BL) is a rare B-cell malignancy characterized by extreme tumor proliferation, frequent extranodal involvement, and the genetic hallmark of a MYC gene rearrangement. Despite an often dramatic initial presentation featuring tumor compression of vital organs and/or spontaneous tumor lysis syndrome, most patients who survive intensive immunochemotherapy induction are cured. Despite limited evidence of benefit, the current NCCN guidelines recommend that BL patients in CR are reviewed every 3 months for 2 years and every 6 months thereafter. Aims: To investigate outcomes, including relative survival and relapse risks conditional on event-free survival (EFS) milestones, in an international study of real-world BL patients treated with intensive immunochemotherapy. Patients and methods: This is a retrospective study of newly diagnosed BL patients identified from relevant population or hospital-based registers in Australia (Perth), Denmark (the Danish Lymphoma Registry), Sweden (the Swedish Lymphoma Registry) and Norway (Health Region South East). Patients who met the following criteria were included irrespective of HIV status: 1) age ≥18 years at diagnosis, 2) diagnosed during the period 2005-2017, 3) histology and immunohistochemistry consistent with BL, 4) MYC translocation detected by fluorescence in situ hybridization (FISH), and 5) intensive first line immunochemotherapy including rituximab (R-CHOEP or more intensive). Patient data were collected from registers and chart reviews. Overall survival (OS) was defined as time until death and EFS was defined as time to death, relapse/progression, or unplanned treatment, whichever came first. Prognostic features at baseline were evaluated using univariate Cox models with EFS as outcome. Standardized mortality ratios (SMRs), conditional relative survival estimates, and relapse risks were computed for the subset of patients achieving complete remission (CR or CRu), with follow-up measured from response evaluation and from different EFS milestones. Results: In total, 159 patients fulfilled the inclusion criteria of the study. The median age was 48 years (range 18-81) and the male:female ratio was 2.9. The baseline characteristics included stage III-IV (75%), elevated serum LDH (75%), extranodal involvement (83% - bone or bone marrow in 42% and CNS in 8%), B symptoms (60%), and ECOG performance score >1 (30%). The chemotherapy protocols used were CHOEP (2%), DA-EPOCH (13%), HYPER-CVAD (26%), CODOX-M/IVAC (28%), BFM or GMALL (31%), and others (1%). Clinical tumor lysis syndrome defined by severe electrolyte derangement, renal impairment, and/or cardiac arrhythmia, was noted in 16% of the patients, but no fatal episodes occurred. The overall response rate to first-line treatment was 88% (87% in CR/CRu) with 67% assessed by PET technology. The five-year EFS and OS estimates for the total population were 75% (95% CI 68-82%) and 82% (95% CI 76-88%), respectively, and the EFS and OS of patients <50 years of age were 81% (95% CI 71-90%) and 89% (95% CI 82-96%), respectively. In univariate analyses, age, advanced stage, and elevated LDH were associated with worse EFS. Among patients in CR/CRu (n=137), the 5-year EFS and OS from the time of response evaluation were 86% (95% CI 79-93%) and 91% (95% CI 86-96%), respectively. The 5-year cumulative incidence of relapse from the time of response assessment was 5% (95% CI 1-9%) in CR/CRu patients. The corresponding estimate was 3% (95% CI 0-6%) for patients alive after 6 months without events (EFS6), whereas no patients relapsed after 12 (EFS12, Figure 1). For CR/CRu patients, the 5-year relative survival after EFS6 and EFS12 was 97% (95% CI 93-102%) and 100% (95% CI 97-103%), respectively. In most subgroups, the SMRs gradually decreased with increased remission duration (Table 1). Conclusions: Outcomes of adult BL patients treated with intensive immunochemotherapy are excellent with no relapses occurring for patients reaching EFS12 and with a normalized relative survival after EFS6. For patients reaching EFS12, follow-up in late effects clinics, or discharging to primary care providers with a focus on survivorship issues rather than detection of recurrent lymphoma, should be considered. Updated analyses including patients from British Columbia (Canada) and the University of Iowa/Mayo Clinic SPORE MER register (USA) will be presented at the meeting. Disclosures Molin: Takeda Pharmaceuticals: Research Funding; Bristol-Myers Squibb: Honoraria; Roche Holding AG: Honoraria; Merck & Co., Inc: Honoraria. Ekstroem Smedby:Janssen Pharmaceuticals: Other: The Department have recieved partial funding from Janssen Pharmaceuticals." @default.
• W2966938034 created "2019-08-22" @default.
• W2966938034 creator A5006888644 @default.
• W2966938034 creator A5008712226 @default.
• W2966938034 creator A5009195100 @default.
• W2966938034 creator A5026722843 @default.
• W2966938034 creator A5031476005 @default.
• W2966938034 creator A5032301959 @default.
• W2966938034 creator A5037129253 @default.
• W2966938034 creator A5037863932 @default.
• W2966938034 creator A5038360792 @default.
• W2966938034 creator A5040068557 @default.
• W2966938034 creator A5040135652 @default.
• W2966938034 creator A5051101456 @default.
• W2966938034 creator A5052653265 @default.
• W2966938034 creator A5053949489 @default.
• W2966938034 creator A5064339706 @default.
• W2966938034 creator A5064956100 @default.
• W2966938034 creator A5065032765 @default.
• W2966938034 creator A5080184636 @default.
• W2966938034 creator A5088720489 @default.
• W2966938034 date "2018-11-29" @default.
• W2966938034 modified "2023-09-30" @default.
• W2966938034 title "Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients" @default.
• W2966938034 doi "https://doi.org/10.1182/blood-2018-99-111748" @default.
• W2966938034 hasPublicationYear "2018" @default.
• W2966938034 type Work @default.
• W2966938034 sameAs 2966938034 @default.
• W2966938034 citedByCount "0" @default.
• W2966938034 crossrefType "journal-article" @default.
• W2966938034 hasAuthorship W2966938034A5006888644 @default.
• W2966938034 hasAuthorship W2966938034A5008712226 @default.
• W2966938034 hasAuthorship W2966938034A5009195100 @default.
• W2966938034 hasAuthorship W2966938034A5026722843 @default.
• W2966938034 hasAuthorship W2966938034A5031476005 @default.
• W2966938034 hasAuthorship W2966938034A5032301959 @default.
• W2966938034 hasAuthorship W2966938034A5037129253 @default.
• W2966938034 hasAuthorship W2966938034A5037863932 @default.
• W2966938034 hasAuthorship W2966938034A5038360792 @default.
• W2966938034 hasAuthorship W2966938034A5040068557 @default.
• W2966938034 hasAuthorship W2966938034A5040135652 @default.
• W2966938034 hasAuthorship W2966938034A5051101456 @default.
• W2966938034 hasAuthorship W2966938034A5052653265 @default.
• W2966938034 hasAuthorship W2966938034A5053949489 @default.
• W2966938034 hasAuthorship W2966938034A5064339706 @default.
• W2966938034 hasAuthorship W2966938034A5064956100 @default.
• W2966938034 hasAuthorship W2966938034A5065032765 @default.
• W2966938034 hasAuthorship W2966938034A5080184636 @default.
• W2966938034 hasAuthorship W2966938034A5088720489 @default.
• W2966938034 hasBestOaLocation W29669380341 @default.
• W2966938034 hasConcept C126322002 @default.
• W2966938034 hasConcept C143998085 @default.
• W2966938034 hasConcept C187212893 @default.
• W2966938034 hasConcept C2778476033 @default.
• W2966938034 hasConcept C2778913318 @default.
• W2966938034 hasConcept C2779338263 @default.
• W2966938034 hasConcept C2780653079 @default.
• W2966938034 hasConcept C2908647359 @default.
• W2966938034 hasConcept C71924100 @default.
• W2966938034 hasConcept C99454951 @default.
• W2966938034 hasConceptScore W2966938034C126322002 @default.
• W2966938034 hasConceptScore W2966938034C143998085 @default.
• W2966938034 hasConceptScore W2966938034C187212893 @default.
• W2966938034 hasConceptScore W2966938034C2778476033 @default.
• W2966938034 hasConceptScore W2966938034C2778913318 @default.
• W2966938034 hasConceptScore W2966938034C2779338263 @default.
• W2966938034 hasConceptScore W2966938034C2780653079 @default.
• W2966938034 hasConceptScore W2966938034C2908647359 @default.
• W2966938034 hasConceptScore W2966938034C71924100 @default.
• W2966938034 hasConceptScore W2966938034C99454951 @default.
• W2966938034 hasIssue "Supplement 1" @default.
• W2966938034 hasLocation W29669380341 @default.
• W2966938034 hasOpenAccess W2966938034 @default.
• W2966938034 hasPrimaryLocation W29669380341 @default.
• W2966938034 hasRelatedWork W1969362652 @default.
• W2966938034 hasRelatedWork W2014502970 @default.
• W2966938034 hasRelatedWork W2046188170 @default.
• W2966938034 hasRelatedWork W2049224842 @default.
• W2966938034 hasRelatedWork W2092717964 @default.
• W2966938034 hasRelatedWork W2165831472 @default.
• W2966938034 hasRelatedWork W2234235408 @default.
• W2966938034 hasRelatedWork W2379928158 @default.
• W2966938034 hasRelatedWork W2899250601 @default.
• W2966938034 hasRelatedWork W2993375378 @default.
• W2966938034 hasVolume "132" @default.
• W2966938034 isParatext "false" @default.
• W2966938034 isRetracted "false" @default.
• W2966938034 magId "2966938034" @default.
• W2966938034 workType "article" @default.